ECLS SARS CoV-2 Addendum Form
Extracorporeal Life Support Organization (ELSO)

Please refer to the ELSO Registry Data Definitions for Details

Unique ID: ______________________

SARS-CoV-2 Co-Morbidity (Select all that apply)

☐ Cancer ☐ Pregnancy
☐ Immunocompromised ☐ Asthma
☐ Diabetes ☐ Chronic lung disease (excluding asthma)
☐ Chronic Renal Insufficiency ☐ Chronic heart disease
☐ Obesity (BMI >30 kg/m²) ☐ Frailty (patients >65 years old)
☐ Hypertension

SARS-CoV-2 Co-Infection (Select all that apply)

☐ Co-viral infection: ☐ Confirmed with RT PCR ☐ Culture confirmed ☐ Suspected
☐ Bacterial pneumonia: ☐ Confirmed with RT PCR ☐ Culture confirmed ☐ Suspected
☐ Blood stream infection: ☐ Confirmed with RT PCR ☐ Culture confirmed ☐ Suspected
☐ Urinary tract infection: ☐ Confirmed with RT PCR ☐ Culture confirmed ☐ Suspected

Acute Co-Diagnoses (Select all that apply)

☐ ARDS ☐ Pneumonia
☐ Septic Shock ☐ Myocarditis
☐ Heart Failure ☐ Acute Renal Failure
☐ Pneumothorax

SARS-CoV-2 Pre-Intubation Respiratory Support (Select all that apply)

☐ BiPAP ☐ CPAP ☐ High Flow Nasal Cannula

SARS-CoV-2 Renal Replacement Therapy Support

Renal Replacement Therapy Required on ECMO? ☐ Yes ☐ No

SARS-CoV-2 Immunomodulator Therapies (Select all that apply)

☐ Steroids: Systemic Glucocorticosteroids ☐ JAK inhibition
☐ IVIG: Intravenous Immunoglobulin ☐ Chloroquine
☐ Selective cytokine blockade (Anakinra or Tocilizumab) ☐ Remdesivir
☐ Lopinavir/Ritonavir (Kaletra) ☐ Aspirin

SARS-CoV-2 Blood Testing

Day of Intubation: (within 24 hours of intubation Pre or Post)

CRP level: _______ ☐ Not measured
Procalcitonin: _______ ☐ Not measured

Pre-ECLS Start: (within 24 hours and/or closest to and before ECLS start)

CRP level: _______ ☐ Not measured
Procalcitonin: _______ ☐ Not measured
SARS-CoV-2 Pre-ECLS Anticoagulation (after hospital admission and before ECLS Initiation)

☐ None
☐ Prophylactic Anticoagulation (anticoagulation agents prescribed without defined metrics of therapeutic effect)
  ☐ Heparin (continuous infusion)
  ☐ Low-Molecular-Weight Heparin
  ☐ Direct Thrombin Inhibitor (bivalirudin, argatroban, etc.)
  ☐ Novel Oral Anticoagulants (NOAC)
  ☐ Other
☐ Targeted Treatment Anticoagulation (anticoagulation agents prescribed with defined goals of therapeutic effect)
  ☐ Heparin (continuous infusion)
  ☐ Low-Molecular-Weight Heparin
  ☐ Direct Thrombin Inhibitor (bivalirudin, argatroban, etc.)
  ☐ Novel Oral Anticoagulants (NOAC)
  ☐ Other

Multi-System Inflammatory Syndrome in Children - MIS-C
These questions refer to those patients less than 21 years old

SARS-CoV-2 Diagnostic Testing (only applicable for MIS-C patients)

☐ Active SARS-CoV-2 infection confirmed by PCR
☐ Prior SARS-CoV-2 infections confirmed by IgG / IgM serology testing
☐ MIS-C suspected without positive laboratory testing

SARS-CoV-2 Organ System Involvement (only applicable for MIS-C patients)

☐ Cardiovascular (please select all clinical manifestation that apply):
  ☐ Systolic ventricular dysfunction by echocardiogram (moderate or severe or ejection fraction <50%)
  ☐ Conduction system disturbance
  ☐ Hemodynamically significant arrhythmia
  ☐ Vasomotor dysfunction / vasoplegia
  ☐ Coronary artery ectasia or aneurysm
☐ Renal
☐ Respiratory
☐ Hematological
☐ Gastrointestinal
☐ Dermatological
☐ Neurological